1. Search Result
Search Result
Results for "

destabilization domain

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112210
    Shield-1
    5+ Cited Publications

    Shld1

    FKBP Others
    Shield-1 (Shld1) is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to mutated FKBP (mtFKBP), allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize proteins tagged with a mutated FKBP12-derived destabilization domain (DD) .
    Shield-1
  • HY-138155

    DNA/RNA Synthesis Cancer
    NSC15520 is a small molecular inhibitor of Replication Protein A (RPA). NSC15520 specifically recognizes the RPA N-terminal DNA binding domain (DBD), and blocks the interaction of RPA with p53 or RAD9. NSC15520 also inhibtis helix destabilization of a duplex DNA (dsDNA) oligonucleotide, involves in DNA replication, DNA repair, DNA recombination, and DNA damage response signaling .
    NSC15520
  • HY-P991180

    TNF Receptor Cancer
    TRX-518 is a humanized agylcosyl IgG1 anti-GITR mAb, , and is a GITR agonist. TRX-518 binds to the extracellular domain of human GITR, abrogates Treg-mediated suppression. TRX-518 increases effector T cell activation and pro-inflammatory cytokine production, reduces circulating and intratumor Treg frequencies. TRX-518 destabilizes Treg phenotype via Foxp3 downregulation and T-bet upregulation. TRX-518 can be used for the research of solid tumors[1][2][3].
    TRX-518
  • HY-113646

    FKBP Others
    Shield-2 is an efficient stabilizing ligand binding to the FKBP (F36V) protein with a dissociation constant of 29 nM. Shield-2 binds tightly to the FKBP mutants destabilizing domains and prevents degradation, thus providing small molecule regulation over intracellular protein levels .
    Shield-2
  • HY-179114

    Biochemical Assay Reagents Others
    VU0519975 is a raft destabilizing compound. VU0519975 reduces PMP22 raft partitioning and destabilizes ordered domains. VU0519975 significantly decreases the fraction of phase separated GPMVs .
    VU0519975
  • HY-183583

    HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-2α-IN-18 is a selective HIF-2α inhibitor with a human IC50 of 8.1 nM. HIF-2α-IN-18 binds to the HIF-2α PAS-B domain, induces conformational perturbations at the HIF-2α/ARNT dimerization interface, destabilizes the HIF-2α/ARNT heterodimer, and blocks HIF-2α-mediated transcriptional activity. HIF-2α-IN-18 inhibits hypoxia-induced expression of HIF-2α target genes EPO and SERPINE1, without inhibiting HIF-1α target genes PGK1 and PDK1. HIF-2α-IN-18 can be used for the research of clear cell renal cell carcinoma, hepatocellular carcinoma[1].
    HIF-2α-IN-18

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: